


The quest for an HIV vaccine

August 19 2020, by Ruth Abrahams, Oxford Science Blog



Credit: AI-generated image ([disclaimer](#))

The UNAIDS estimates that 38 million people currently live with human immunodeficiency virus (HIV) infection. Combination antiretroviral treatment has had great success in saving lives but is also associated with numerous medical and public health challenges. Vaccination remains the best and most cost-effective option for controlling HIV infection across the world. Professor Tomáš Hanke jointly from the University of Oxford, UK, and Kumamoto University, Japan, designs vaccines and

coordinates clinical programs testing the most advanced vaccine candidates developed by his team in the UK, Europe, U.S. and Africa.

Ending AIDS with vaccination

Human immunodeficiency virus (HIV) type 1 represents 95% of all HIV infections worldwide and is responsible for the global HIV pandemic. If untreated, HIV-infected patients develop acquired immunodeficiency syndrome—better known as AIDS—that manifests as a progressive failure of their immune system. As a result, patients eventually succumb to opportunistic infections. Combination antiretroviral treatment (cART) has transformed the lives of people living with HIV, and dramatically decreased AIDS-related mortality and onward transmission of HIV.

Unfortunately, the provision of cART to everybody who needs it faces many obstacles particularly in low- and middle-income countries. The cost, complexity of the treatment, necessity of regular monitoring of patients, threat of drug resistance, side effects, social stigma and the use of cART to prevent HIV infections (or pre-exposure prophylaxis), which further stretches the cART supply, make cART a suboptimal therapeutic and an unlikely stand-alone tool to end the HIV epidemic. Therefore, an effective [vaccine](#) for both prevention and cure of HIV is urgently needed.

Professor Tomáš Hanke and his team at the Jenner Institute at the University of Oxford, UK, together with their collaborators at the Joint Research Center for Human Retrovirus Infection, Kumamoto University, Japan, are studying T cell responses to HIV to inform vaccine development. In addition, Professor Hanke oversees Experimental Medicine trials of his leading T-cell vaccine candidates in healthy and HIV-positive people at several global sites and collaborates with prestigious universities and organizations such as the International AIDS Vaccine Initiative, IrsiCaixa AIDS Research Institute-HIVACAT

in Spain, Imperial College London, the Kenya AIDS Vaccine Initiative-Institute for Clinical Research and National Institute of Allergy and Infectious Diseases. He also co-ordinates the "Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership" consortium, acronymed GREAT, which builds research capacity and tests vaccine candidates in Eastern and Southern Africa, and is one of the principal investigators of the European AIDS Vaccine Initiative 2020.

Rational iterative development

Most of today's HIV vaccine research focuses on antibody-mediated immunity, which neutralizes cell-free viruses and typically involves exposing people to the outer HIV spike. However, to achieve HIV control, antibodies may need to be complemented by T-cell responses, the focus of Professor Hanke's research. There is no doubt that T cells contribute in an important way to anti-HIV immunity, whereby CD8 T cells known as "killer cells" directly kill virus-infected cells, the virus factories, and CD4 T cells or 'helper cells' assist and co-ordinate antibody and T-cell induction. "The trick is to induce not just any, but protective killer T cells that can slow or stop HIV," explains Professor Hanke.

The first clinically tested vaccine that Professor Hanke and his colleagues developed was called HIVA. It was derived from an African clade A strain of HIV and was tested in over a dozen clinical trials. Following the field's full appreciation of the HIV's enormous ability to change, Professor Hanke improved his approach by focusing vaccine-elicited T cells on the functionally conserved regions of HIV, which are common to most HIV strains and essential for virus survival. If successful, such a vaccine could be deployed universally in all global regions.

The prototype conserved immunogen was called HIVconsv (to

emphasize conserved in addition to consensus sequences) and assembled highly conserved HIV regions into a chimeric protein alternating the global major HIV strains. This vaccine showed encouraging results in initial small clinical trials and informed the design of the second-generation conserved vaccines called HIVconsvX. Notable HIVconsvX improvements include the use of bioinformatics to redefine conserved regions and increase the vaccine match to the global HIV variants by using a so-called "mosaic" design. The HIVconsvX vaccines entered clinical evaluation in 2019 with further trials in the pipeline.

The importance of vaccine vectors

The quality of vaccine-elicited T-cell responses is strongly influenced by the way HIV immunogens are introduced into the body. The utmost priority is safety and Professor Hanke and his colleagues test all potential vaccine vectors intended for human use in mice and macaques first. The three most promising modalities that progressed in combination to [human studies](#) were 1) plasmid DNA, 2) engineered adenovirus of chimpanzee origin, the parent of which causes a common cold-like disease in monkeys, and 3) a poxvirus modified vaccinia virus Ankara (MVA), an attenuated smallpox vaccine used safely in many people during the smallpox eradication campaign. None of these three vaccines is replication-competent and can grow in the vaccinees' body or spread to the environment; they are safe.

The HIVA vaccine was delivered by a combination of DNA and MVA and induced only weak T-cell responses mainly because of the inefficient DNA prime. Induction of T cells by the HIVconsv vaccines was greatly improved by the addition of the chimpanzee adenovirus. However, the adenovirus-MVA combination without DNA was as good as all the three vectors together and was therefore chosen for further studies.

HIVconsv vaccination-induced strong T cells that recognized multiple sites on the HIV. Vaccine-elicited T cells in HIV-negative volunteers in Nairobi, Kenya, were capable of a broad cross-clade inhibition of HIV under laboratory conditions. The HIVconsv vaccines were also tested in 'kick-and-kill' studies in early treated HIV-positive individuals. During infection, HIV integrates into the host chromosome, stops expressing its proteins ("falls asleep") and becomes invisible to the immune system, but regularly reactivates. This means that to eliminate HIV from the body, all sleeping HIV first needs to be awakened, or 'kicked' before it can be killed by the vaccine-induced killer T cells.

In a small pilot "kick-and-kick" study in Barcelona, Spain, the HIVconsv vaccines together with an HIV-reactivating drug provided a signal of sustained suppression of HIV replication after stopping cART. Although a marginal result, it was very encouraging and warranted further testing of the "kick-and-kill" strategy with these vaccines as an HIV cure.

Understanding the consequences of HIV variability

A successful vaccine needs to elicit killer T cells capable of reaching HIV-infected cells and killing them to stop virus growth. To be safe and effective, the killer T-cell assault must be sufficiently specific and efficiently target vulnerable parts of the HIV from the very first exposure to the virus. However, HIV is extremely variable and this makes it very good at avoiding the T-cell attack and escaping. There is lots of supporting evidence that people's genetic makeup, the sites on HIV that killer T cells target and HIV escape are the major determinants of how well individuals fight HIV and scientists need to understand these processes in great detail.

Some T-cell responses are better at protecting than others. In the past, attempts to understand which parts of HIV should be targeted for protection often looked at responses to the whole virus and/or full-length

virus proteins as units. This blurred the analysis because within each protein there are both stable and variable regions and these are not equally protective. Professor Hanke's strategy exploits the stable and therefore vulnerable parts on HIV proteins.

This idea was supported by studies of Professor Hanke's colleagues at Kumamoto and Tokyo Universities. HIV-infected patients, who never received any cART, controlled HIV better and were healthier (had more CD4 cells in the blood) if they targeted the same regions as used in the vaccine. This is an important observation endorsing this vaccine approach.

The quest for improvement

Although Professor Hanke's strategy is rational and, so far, supported by good experimental results, many challenges remain on the road to an effective T-cell vaccine.

To be efficient, T-cell responses must, upon HIV exposure/reactivation, rapidly reach the sites of HIV growth within the patient's body, kill infected cells and produce anti-HIV chemicals, be in sufficient numbers, and recognize multiple vulnerable regions at the same time to make escape difficult. It is plausible that if any one aspect of these T-cell properties is suboptimal, the vaccine may fail.

Professor Hanke and his colleagues study T-cell responses induced by HIV infection and vaccination in order to further refine the vaccine immunogens and their vector delivery. Novel and sometimes small but significant step-by-step improvements are tested in pre-clinical investigations and human trials. "Iterative improvements are best informed by human data, the only species that ultimately matters," says Professor Hanke.

Finally, new-born babies, children and adolescents, some of whom have acquired HIV perinatally, that is, via mother-to-child transmission, or babies who are exposed to HIV through mother's milk, remain somewhat unique populations because of their young and, if treated soon after birth, relatively preserved immune system. To date, there have been several hundred HIV vaccine trials in humans, but only a very few tested candidate HIV vaccines in these age groups. Yet, childhood vaccines are the biggest success of vaccinology. Professor Hanke and his colleagues tested the HIVA vaccine in African neonates as the first step towards preventing mother-to-child transmission through breastfeeding and are planning to revisit these age groups using the conserved mosaic vaccines.

Provided by University of Oxford

Citation: The quest for an HIV vaccine (2020, August 19) retrieved 25 April 2024 from <https://medicalxpress.com/news/2020-08-quest-hiv-vaccine.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.